021-51111890
购物车（）
sales@molnova.cn
DNQX Disodium
CAS No. 1312992-24-7
DNQX Disodium ( —— )
产品货号. M21938 CAS No. 1312992-24-7
DNQX Disodium 是一种水溶性形式的非 NMDA 受体选择性拮抗剂。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥1159 | 有现货 |
|
| 10MG | ￥1720 | 有现货 |
|
| 25MG | ￥2678 | 有现货 |
|
| 50MG | ￥3636 | 有现货 |
|
| 100MG | ￥4725 | 有现货 |
|
| 200MG | ￥6210 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ￥1074 | 有现货 |
|
生物学信息
-
产品名称DNQX Disodium
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述DNQX Disodium 是一种水溶性形式的非 NMDA 受体选择性拮抗剂。
-
产品描述DNQX Disodium is a water-soluble form of selective antagonist of non-NMDA receptor.
-
体外实验DNQX (FG 9041) disodium salt selectively depolarizes thalamic reticular nucleus (TRN) neurons.
-
体内实验DNQX (FG 9041), a specific AMPA receptor antagonist, given as either a 5 mg/kg or 10 mg/kg intraperitoneal dose or into the lateral cerebral ventricle (5 μl of 0.5 mg/ml) significantly diminishes phencyclidine (PCP) (40 mg/kg) and ketamine (80, 100, 120 mg/kg) hsp70 induction in the posterior cingulate and retrosplenial cortex.
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体non-NMDA
-
研究领域——
-
适应症——
化学信息
-
CAS Number1312992-24-7
-
分子量296.1
-
分子式C8H2N4Na2O6
-
纯度>98% (HPLC)
-
溶解度——
-
SMILES[Na+].[Na+].[O-]c1nc2cc(c(cc2nc1[O-])[N+]([O-])=O)[N+]([O-])=O
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
-
GNE-1858
GNE-1858 是一种 ATP 竞争性造血祖激酶-1 (HPK1) 抑制剂（野生型和活性模拟突变体 HPK1-TSEE 和 HPK1-SA 的 IC50 分别为 1.9 nM、1.9 nM 和 4.5 nM）。
-
PACAP (1-38), human,...
PACAP (1-38), a novel neuropeptide isolated from the bovine hypothalamus is more active than vasoactive intestinal peptide (VIP) in stimulating adenylate cyclase (EC50=7 nM). PACAP 1-38 (10-9 M) increased substance P (SP), gastrin releasing peptide (GRP), and VIP release. PACAP 1-38 (10-8 M) inhibited gastrin secretion and stimulated somatostatin secretion and motility dose-dependently.
-
Zilovertamab
Zilovertamab (UC-961) is a humanized anti-ROR1 monoclonal antibody that cuts off the WNT5A-induced ROR1 signaling pathway and shows anti-proliferative activity in ovarian and endometrial cancer cells. It can be used to study lymphatic cancer.
